Growing evidence shows that RPS6KB1 overexpression/activation is a critical driver of initiation and progression of tumors, and that the inactivation of RPS6KB1 may be therapeutically effective in many types of cancer [29–32]. This evidence concerns the gene RPS6KB1 and cancer.